Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update

Clinical Pharmacokinetics

Volumn 54, Issue 11, 2015, Pages 1125-1138

  Teng, Renli ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLOSPORIN; CYTOCHROME P450 2C19; DIGOXIN; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN 1; ORAL CONTRACEPTIVE AGENT; PRASUGREL; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; VENLAFAXINE; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; GENOTYPE; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOKINETICS; PLEIOTROPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANALOGS AND DERIVATIVES; ANIMAL; METABOLISM; ORAL DRUG ADMINISTRATION;

ACUTE CORONARY SYNDROME; ADENOSINE; ADMINISTRATION, ORAL; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84945455640     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0290-2     Document Type: Review

References (92)

1. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64:2645–87.
2. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–292.
3. Libby P, Tabas I, Fredman G, Fisher EA. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res. 2014;114:1867–79.
4. Crea F, Liuzzo G. Pathogenesis of acute coronary syndromes. J Am Coll Cardiol. 2013;61:1–11.
5. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:e78–140.
6. Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the Management of Acute Coronary Syndromes (ACS) in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999–3054.
7. Steg PG, James SK, Atar D, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the Management of ST-Segment Elevation Myocardial Infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012;33:2569–619.
8. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.
9. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244–7.
10. Sorich MJ, Rowlan A, McKinnon RA, Wiese MD. CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following PCI and in Asian populations treated with clopidogrel: a meta-analysis. Circ Cardiovasc Genet. 2014;7:895–902.
11. Tresukosol D, Suktitipat B, Hunnangkul S, et al. Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. PLos One. 2014;9:e110188.
12. Jakubowski JA, Matsushima N, Asai F, et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol. 2007;63:421–30.
13. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.
14. van Giezen JJ, Nilsson L, Berntsson P, et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009;7:1556–65.
15. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.
16. Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–800.
17. Teng R. Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. Clin Pharmacokinet. 2012;51:305–18.
18. Teng R, Maya J. Absolute bioavailability and regional absorption of ticagrelor in healthy volunteers. J Drug Assess. 2014;3:43–50.
19. 12 receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 2010;66:487–96.
20. Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010;38:1514–21.
21. Teng R, Carlson G, Hsia J. An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers. Int J Clin Pharmacol Ther. 2015;53:182–9.
22. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50:1852–6.
23. Butler K, Teng R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol. 2010;70:65–77.
24. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038–47.
25. Husted SE, Storey RF, Bliden K, et al. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. Clin Pharmacokinet. 2012;51:397–409.
26. Teng R, Mitchell PD, Butler K. Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers. J Clin Pharm Ther. 2012;37:464–8.
27. 12 receptor antagonist, in mice, rats, and marmosets. Drug Metab Dispos. 2011;39:1555–67.
28. Zhou D, Andersson TB, Grimm SW. In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction and differential kinetics. Drug Metab Dispos. 2011;39:703–10.
29. AstraZeneca LP. Brilinta (ticagrelor) tablets. Approved prescribing information. Updated Mar 29, 2013. Available at: http://www1.astrazeneca-us.com/pi/brilinta.pdf. Accessed 24 Mar 2015.
30. Sanofi, Bristol-Myers Squibb. Plavix (clopidogrel bisulfate) tablets. Approved prescribing information. Updated Dec 2013. Available at: http://packageinserts.bms.com/pi/pi_plavix.pdf. Accessed 27 Mar 2015.
31. Eli Lilly and Company. Effient (prasugrel) tablets. Approved prescribing information. Updated Nov 2013. Available at: http://pi.lilly.com/us/effient.pdf. Accessed 27 Mar 2015.
32. Teng R, Mitchell P, Butler K. Effect of age and gender on the pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy subjects. Eur J Clin Pharmacol. 2012;68:1175–82.
33. Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment. J Clin Pharmacol. 2012;52:1388–98.
34. Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment. J Clin Pharmacol. 2011;51:978–87.
35. 12 antagonism. J Thromb Haemost. 2013;11:1867–76.
36. Belchikov YG, Koenig SJ, Dipasquale EM. Potential role of endogenous adenosine in ticagrelor-induced dyspnea. Pharmacotherapy. 2013;33:882–7.
37. Burki NK, Dale WJ, Lee LY. Intravenous adenosine and dyspnea in humans. J Appl Physiol. 1985;2005(98):180–5.
38. Burki NK, Alam M, Lee LY. The pulmonary effects of intravenous adenosine in asthmatic subjects. Respir Res. 2006;7:139.
39. Butler K, Maya J, Teng R. Effect of ticagrelor on pulmonary function in healthy elderly volunteers and asthma or chronic obstructive pulmonary disease patients. Curr Med Res Opin. 2013;29:569–77.
40. Waksman R, Maya J, Angiolillo D, et al. Ticagrelor versus clopidogrel in African American patients with coronary artery disease and diabetes mellitus. J Am Coll Cardiol. 2014;63(12_S):A211.
41. Li H, Butler K, Yang L, Yang Z, Teng R. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. Clin Drug Invest. 2012;32:87–97.
42. Teng R, Butler K. Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers. Int J Clin Pharmacol Ther. 2014;52:478–91.
43. Hiasa Y, Teng R, Emanuelsson H. Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. Cardiovasc Interv Ther. 2014;29:324–33.
44. Price MJ, Clavijo L, Angiolillo D, et al. A randomized trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease. J Thromb Thrombolysis. 2014;39:8–14.
45. Waksman R, Maya J, Angiolillo D, et al. Ticagrelor versus clopidogrel in African American patients with stable coronary artery disease: a randomized, open-label, multiple-dose, crossover study. J Am Coll Cardiol Intv. 2014;7(2_S):S6 Abstract CRT-99.
46. Teng R, Butler K. The effect of ticagrelor on the metabolism of midazolam in healthy volunteers. Clin Ther. 2013;35:1025–37.
47. Teng R, Mitchell P, Butler K. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol. 2013;69:477–87.
48. Butler K, Teng R. Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteers. Curr Med Res Opin. 2011;27:1585–93.
49. Teng R, Mitchell P, Butler K. Evaluation of the pharmacokinetic interaction between ticagrelor and tolbutamide, a cytochrome P45 2C9 substrate, in healthy volunteers. Int J Clin Pharmacol Ther. 2013;51:305–12.
50. Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013;34:1708–13.
51. Teng R, Kujacic M, Hsia J. Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. Clin Ther. 2014;36:1217–25.
52. Teng R, Butler K. A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. Eur J Clin Pharmacol. 2013;69:1801–8.
53. Teng R, Mitchell P, Butler K. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects. Eur J Clin Pharmacol. 2013;69:877–83.
54. Holmberg MT, Tornio A, Joutsi-Korhonen L, et al. Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects. Br J Clin Pharmacol. 2013;75:1488–96.
55. Teng R, Butler K. Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers. J Drug Assess. 2013;2:30–9.
56. Teng R, Kujacic M, Hsia J. Effect of the cyclosporine on ticagrelor pharmacokinetics in healthy volunteers. Clin Drug Investig. 2014;34:529–36.
57. Teng R, Butler K. Lack of clinically significant pharmacological interactions between ticagrelor and enoxaparin or unfractionated heparin in healthy subjects. J Clin Pharm Ther. 2012;37:704–11.
58. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial. Circulation. 2011;124:544–54.
59. Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther. 2009;27:259–74.
60. 12 receptor in a murine laser-injury model. J Thromb Haemost. 2007;5(Suppl 1):P-W-632.
61. Guthikonda S, Alviar CL, Vaduganathan M, et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol. 2008;52:743–9.
62. Kuijpers MJE, Megens RTA, Nikookhesal E, et al. Role of newly formed platelets in thrombus formation after clopidogrel treatment: comparison to the reversible P2Y12 antagonist ticagrelor. Thromb Haemost. 2011;106:1179–88.
63. Teng R, Mitchell P, Butler K. The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor. J Clin Pharm Ther. 2014;39:186–91.
64. Buchanan A, Newton P, Pehrsson S, et al. Structural and functional characterisation of a specific antidote for ticagrelor. Blood. 2015;125:3484–90.
65. Vilahur G, Choi BG, Zafar MU, et al. Normalization of platelet reactivity in clopidogrel-treated subjects. J Thromb Haemost. 2007;5:82–90.
66. Prüller F, Drexler C, Archan S, Macher S, Raggam RB, Mahla E. Low platelet reactivity is recovered by transfusion of stored platelets: a healthy volunteer in vivo study. J Thromb Haemost. 2011;9:1670–3.
67. Armstrong D, Summers C, Ewart L, Nylander S, Sidaway JE, Van Giezen H. Characterisation of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter-1. J Cardiovasc Pharmacol Ther. 2014;19:209–19.
68. Wittfeldt A, Emanuelsson H, Brandrup-Wognsen G, et al. Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. J Am Coll Cardiol. 2013;61:723–7.
69. Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014;63:2503–9.
70. Nanhwan MK, Ling S, Kodakandla M, Nylander S, Ye Y, Birnbaum Y. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arterioscler Thromb Vasc Biol. 2014;34:2078–85.
71. Reiner MF, Stivala S, Akhmedov A, et al. Cell-specific off-target effects of ticagrelor but not clopidogrel-active metabolite in endothelial dysfunction. Eur Heart J. 2014;35(Suppl 1):199.
72. Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. JAMA. 2007;298:765–75.
73. Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57:672–84.
74. Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes. J Am Coll Cardiol. 2010;561:1456–62.
75. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007;50:1844–51.
76. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013;61:1601–6.
77. Alexopoulos D, Gkizas V, Patsilinakos S, et al. Double versus standard loading dose of ticagrelor: onset of antiplatelet action in patients with STEMI undergoing primary PCI. J Am Coll Cardiol. 2013;62:940–1.
78. Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012;5:797–804.
79. Sugidachi A, Ohno K, Ogawa T, Jakubowski J, Hashimoto M, Tomizawa A. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. Br J Pharmacol. 2013;169:82–9.
80. Parodi G, Xanthopoulou I, Bellandi B, et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J Am Coll Cardiol. 2015;65:511–2.
81. Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel non-responders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121:1188–99.
82. The Medicines Company UK Ltd. Kengrexal (cangrelor) powder. Patient information leaflet. Updated Apr 8, 2015. Available at: https://www.medicines.org.uk/emc/medicine/30245. Accessed 13 Apr 2015.
83. Akers WS, Oh JJ, Oestreich JH, Ferraris S, Wethington M, Steinhubl SR. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol. 2010;50:27–35.
84. Ravnefjord A, Weilitz J, Emanuelsson BM, van Giezen JJ. Evaluation of ticagrelor pharmacodynamic interactions with reversibly-binding or non-reversibly-binding P2Y12 antagonists in an ex-vivo canine model. Thromb Res. 2012;130:622–8.
85. Schneider DJ, Agarwal Z, Seecheran N, Keating FK, Gogo P. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc Interv. 2014;7:435–42.
86. Angiolillo DJ, Curzen N, Gurbel P, et al. Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: results of the SWAP-2 study (Switching Anti Platelet-2). J Am Coll Cardiol. 2014;63:1500–9.
87. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109:3171–5.
88. Müller I, Besta F, Schulz C, Massberg S, Schönig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003;89:783–7.
89. Tantry US, Bliden KP, Wei C, et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet. 2010;3:556–66.
90. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376:1320–8.
91. Akerblom A, Eriksson N, Wallentin L, et al. Polymorphism of the cystatin C gene in patients with acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes Study. Am Heart J. 2014;168(96–102):e2.
92. Varenhorst CMH, Eriksson N, Johansson Å, et al. Ticagrelor plasma levels but not clinical outcomes are associated with transporter and metabolism enzyme genetic polymorphisms. J Am Coll Cardiol. 2014;63(12_S):A25.